These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 22114551)

  • 21. Activity of VT-1129 against Cryptococcus neoformans clinical isolates with high fluconazole MICs.
    Nielsen K; Vedula P; Smith KD; Meya DB; Garvey EP; Hoekstra WJ; Schotzinger RJ; Boulware DR
    Med Mycol; 2017 Jun; 55(4):453-456. PubMed ID: 27664991
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Amino acid substitution in Cryptococcus neoformans lanosterol 14-α-demethylase involved in fluconazole resistance in clinical isolates.
    Bosco-Borgeat ME; Mazza M; Taverna CG; Córdoba S; Murisengo OA; Vivot W; Davel G
    Rev Argent Microbiol; 2016; 48(2):137-42. PubMed ID: 27311753
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Polyploid titan cells produce haploid and aneuploid progeny to promote stress adaptation.
    Gerstein AC; Fu MS; Mukaremera L; Li Z; Ormerod KL; Fraser JA; Berman J; Nielsen K
    mBio; 2015 Oct; 6(5):e01340-15. PubMed ID: 26463162
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Characterization of heteroresistance to fluconazole among clinical isolates of Cryptococcus neoformans.
    Yamazumi T; Pfaller MA; Messer SA; Houston AK; Boyken L; Hollis RJ; Furuta I; Jones RN
    J Clin Microbiol; 2003 Jan; 41(1):267-72. PubMed ID: 12517859
    [TBL] [Abstract][Full Text] [Related]  

  • 25. High Prevalence of HIV-Related Cryptococcosis and Increased Resistance to Fluconazole of the
    Yang C; Bian Z; Blechert O; Deng F; Chen H; Li Y; Yang Y; Chen M; Zhan P
    Front Cell Infect Microbiol; 2021; 11():723251. PubMed ID: 34790585
    [TBL] [Abstract][Full Text] [Related]  

  • 26. An Atypical ABC Transporter Is Involved in Antifungal Resistance and Host Interactions in the Pathogenic Fungus Cryptococcus neoformans.
    Winski CJ; Qian Y; Mobashery S; Santiago-Tirado FH
    mBio; 2022 Aug; 13(4):e0153922. PubMed ID: 35726920
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Molecular epidemiology and in vitro antifungal susceptibility testing of 108 clinical Cryptococcus neoformans sensu lato and Cryptococcus gattii sensu lato isolates from Denmark.
    Hagen F; Hare Jensen R; Meis JF; Arendrup MC
    Mycoses; 2016 Sep; 59(9):576-84. PubMed ID: 27061834
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Increase of reactive oxygen species contributes to growth inhibition by fluconazole in Cryptococcus neoformans.
    Dbouk NH; Covington MB; Nguyen K; Chandrasekaran S
    BMC Microbiol; 2019 Nov; 19(1):243. PubMed ID: 31694529
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Identification of a Cryptococcus neoformans cytochrome P450 lanosterol 14α-demethylase (Erg11) residue critical for differential susceptibility between fluconazole/voriconazole and itraconazole/posaconazole.
    Sionov E; Chang YC; Garraffo HM; Dolan MA; Ghannoum MA; Kwon-Chung KJ
    Antimicrob Agents Chemother; 2012 Mar; 56(3):1162-9. PubMed ID: 22155829
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Wild-type MIC distributions and epidemiologic cutoff values for fluconazole, posaconazole, and voriconazole when testing Cryptococcus neoformans as determined by the CLSI broth microdilution method.
    Pfaller MA; Castanheira M; Diekema DJ; Messer SA; Jones RN
    Diagn Microbiol Infect Dis; 2011 Nov; 71(3):252-9. PubMed ID: 21917395
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Antifungal susceptibility testing with YeastONE™ is not predictive of clinical outcomes of Cryptococcus neoformans var. grubii fungemia.
    Yang JH; Huang PY; Cheng CW; Shie SS; Lin ZF; Yang LY; Lee CH; Wu TS
    Med Mycol; 2021 Nov; 59(11):1114-1121. PubMed ID: 34374784
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Azole drugs are imported by facilitated diffusion in Candida albicans and other pathogenic fungi.
    Mansfield BE; Oltean HN; Oliver BG; Hoot SJ; Leyde SE; Hedstrom L; White TC
    PLoS Pathog; 2010 Sep; 6(9):e1001126. PubMed ID: 20941354
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Azole heteroresistance in Cryptococcus neoformans: emergence of resistant clones with chromosomal disomy in the mouse brain during fluconazole treatment.
    Sionov E; Chang YC; Kwon-Chung KJ
    Antimicrob Agents Chemother; 2013 Oct; 57(10):5127-30. PubMed ID: 23836187
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A defect in iron uptake enhances the susceptibility of Cryptococcus neoformans to azole antifungal drugs.
    Kim J; Cho YJ; Do E; Choi J; Hu G; Cadieux B; Chun J; Lee Y; Kronstad JW; Jung WH
    Fungal Genet Biol; 2012 Nov; 49(11):955-66. PubMed ID: 22975303
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Molecular epidemiology and antifungal susceptibility of Cryptococcus neoformans isolates from Ugandan AIDS patients.
    Pfaller M; Zhang J; Messer S; Tumberland M; Mbidde E; Jessup C; Ghannoum M
    Diagn Microbiol Infect Dis; 1998 Nov; 32(3):191-9. PubMed ID: 9884835
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Overexpression of TUF1 restores respiratory growth and fluconazole sensitivity to a Cryptococcus neoformans vad1Delta mutant.
    Panepinto JC; Misener AL; Oliver BG; Hu G; Park YD; Shin S; White TC; Williamson PR
    Microbiology (Reading); 2010 Aug; 156(Pt 8):2558-2565. PubMed ID: 20430817
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Fluconazole induces ROS in Cryptococcus neoformans and contributes to DNA damage in vitro.
    Peng CA; Gaertner AAE; Henriquez SA; Fang D; Colon-Reyes RJ; Brumaghim JL; Kozubowski L
    PLoS One; 2018; 13(12):e0208471. PubMed ID: 30532246
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Synergistic antifungal activity of berberine derivative B-7b and fluconazole.
    Li LP; Liu W; Liu H; Zhu F; Zhang DZ; Shen H; Xu Z; Qi YP; Zhang SQ; Chen SM; He LJ; Cao XJ; Huang X; Zhang JD; Yan L; An MM; Jiang YY
    PLoS One; 2015; 10(5):e0126393. PubMed ID: 25992630
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Predominance of Cryptococcus neoformans var. grubii multilocus sequence type 5 and emergence of isolates with non-wild-type minimum inhibitory concentrations to fluconazole: a multi-centre study in China.
    Fan X; Xiao M; Chen S; Kong F; Dou HT; Wang H; Xiao YL; Kang M; Sun ZY; Hu ZD; Wan Z; Chen SL; Liao K; Chu YZ; Hu TS; Zou GL; Hou X; Zhang L; Zhao YP; Xu YC; Liu ZY
    Clin Microbiol Infect; 2016 Oct; 22(10):887.e1-887.e9. PubMed ID: 27432767
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antifungal susceptibility of clinical and environmental Cryptococcus neoformans and Cryptococcus gattii isolates in Jabalpur, a city of Madhya Pradesh in Central India.
    Gutch RS; Nawange SR; Singh SM; Yadu R; Tiwari A; Gumasta R; Kavishwar A
    Braz J Microbiol; 2015; 46(4):1125-33. PubMed ID: 26691471
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.